Eleanor Jing Yi Cheong
Research Subjects
Eleanor Jing Yi Cheong has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Boon Ling Tay
Singapore Institute of Food and Biotechnology Innovation (SIFBI), Agency for Science, Technology and Research (A*STAR), 31 Biopolis Way, Nanos, Singapore 138669, Republic of Singapore
1 shared publicationCorie A. Ellison
The Procter & Gamble Company, 8700 Mason Montgomery Rd., Mason, OH, 45040, USA
1 shared publication- Eric Chun Yong Chan
Department of Pharmacy and Pharmaceutical Sciences, Faculty of Science National University of Singapore Singapore Singapore
1 shared publication Ervin Zhi Bin Cheong
Department of Pharmacy, Faculty of Science, National University of Singapore, Singapore, Singapore
1 shared publication- Gang Yan
Global Product Stewardship, The Procter & Gamble Company, 8700 Mason Montgomery Rd., Mason, Ohio 45040, United States
1 shared publication - Geraldine Oh
Singapore Institute of Food and Biotechnology Innovation (SIFBI), Agency for Science, Technology and Research (A*STAR), 31 Biopolis Way, Nanos, Singapore 138669, Republic of Singapore
1 shared publication
Latest Publications
- Open Access
- 19 May 2026
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 215, 116169
Development and prospective validation of a read-across approach to assess the in vivo toxicokinetic profiles of chemicals in humans
- 19 May 2026
- Published by Elsevier in Food and Chemical Toxicology
- Vol. 215, 116169
Open AccessDevelopment and prospective validation of a read-across approach to assess the in vivo toxicokinetic profiles of chemicals in humans
- 5 July 2023
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 62 (9) , 1243-1261
Unraveling Complexities in the Absorption and Disposition Kinetics of Abiraterone via Iterative PBPK Model Development and Refinement
Background and Objective Abiraterone is a first-in-class inhibitor of cytochrome P450 17A1 (CYP17A1), and its pharmacokinetic (PK) profile is susceptible to intrinsic and extrinsic variabilities. Potential associations between abiraterone concentrations and pharmacodynamic consequences in prostate cancer may demand further dosage optimization to balance therapeutic outcomes. Consequently, we aim to develop a physiologically based pharmacokinetic (PBPK) model for abiraterone via a middle-out approach to prospectively interrogate the untested, albeit clinically relevant, scenarios. Methods To characterize in vivo hydrolysis of prodrug abiraterone acetate (AA) and supersaturation of abiraterone, in vitro aqueous solubility data, biorelevant measurements, and supersaturation and precipitation parameters were utilized for mechanistic absorption simulation. CYP3A4-mediated N-oxidation and sulfotransferase 2A1-catalyzed sulfation of abiraterone were subsequently quantified in human liver subcellular systems. Iterative PBPK model refinement involved evaluation of potential organic anion transporting polypeptide (OATP)-mediated abiraterone uptake in transfected cells in the absence and presence of albumin. Results The developed PBPK model recapitulated the duodenal concentration–time profile of both AA and abiraterone after simulated AA administration. Our findings established abiraterone as a substrate of hepatic OATP1B3 to recapitulate its unbound metabolic intrinsic clearance. Further consideration of a transporter-induced protein-binding shift established accurate translational scaling factors and extrapolated the sinusoidal uptake process. Subsequent simulations effectively predicted the PK of abiraterone upon single and multiple dosing. Conclusion Our systematic development of the abiraterone PBPK model has demonstrated its application for the prospective interrogation of the individual or combined influences of potential interindividual variabilities influencing the systemic exposure of abiraterone.
- 5 July 2023
- Published by Springer Nature in Clinical Pharmacokinetics
- Vol. 62 (9) , 1243-1261
Unraveling Complexities in the Absorption and Disposition Kinetics of Abiraterone via Iterative PBPK Model Development and Refinement
Background and Objective Abiraterone is a first-in-class inhibitor of cytochrome P450 17A1 (CYP17A1), and its pharmacokinetic (PK) profile is susceptible to intrinsic and extrinsic variabilities. Potential associations between abiraterone concentrations and pharmacodynamic consequences in prostate cancer may demand further dosage optimization to balance therapeutic outcomes. Consequently, we aim to develop a physiologically based pharmacokinetic (PBPK) model for abiraterone via a middle-out approach to prospectively interrogate the untested, albeit clinically relevant, scenarios. Methods To characterize in vivo hydrolysis of prodrug abiraterone acetate (AA) and supersaturation of abiraterone, in vitro aqueous solubility data, biorelevant measurements, and supersaturation and precipitation parameters were utilized for mechanistic absorption simulation. CYP3A4-mediated N-oxidation and sulfotransferase 2A1-catalyzed sulfation of abiraterone were subsequently quantified in human liver subcellular systems. Iterative PBPK model refinement involved evaluation of potential organic anion transporting polypeptide (OATP)-mediated abiraterone uptake in transfected cells in the absence and presence of albumin. Results The developed PBPK model recapitulated the duodenal concentration–time profile of both AA and abiraterone after simulated AA administration. Our findings established abiraterone as a substrate of hepatic OATP1B3 to recapitulate its unbound metabolic intrinsic clearance. Further consideration of a transporter-induced protein-binding shift established accurate translational scaling factors and extrapolated the sinusoidal uptake process. Subsequent simulations effectively predicted the PK of abiraterone upon single and multiple dosing. Conclusion Our systematic development of the abiraterone PBPK model has demonstrated its application for the prospective interrogation of the individual or combined influences of potential interindividual variabilities influencing the systemic exposure of abiraterone.